

Extraordinary General Meeting in Forward Pharma A/S (In voluntary liquidation)

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

An extraordinary general meeting in Forward Pharma A/S (In voluntary liquidation) will be held on

26 November 2025 at 18:00 (CET)

at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark.

AGENDA

- (a) The liquidator's report on the affairs of the company since the latest annual report.
- (b) Presentation of the audited final liquidation accounts for approval.
- (c) Resolution regarding final liquidation and distribution of liquidation proceeds.
- (d) Authorization of the chairperson of the meeting.

THE AGENDA AND THE COMPLETE PROPOSED RESOLUTIONS

Item (b):

The final liquidation accounts, covering the period from 1 January to 31 October 2025, show a loss of DKK 13,954,077 and a liquidation balance of DKK 474,376,156.

The liquidator proposes that the final liquidation accounts be approved substantially in accordance with the draft minutes of general meeting attached hereto as Annex 1.

Item (c):

The liquidator proposes the dissolution of the company and the distribution of the liquidation proceeds to the company's shareholders, thereby completing the liquidation of the company, substantially in accordance with the draft minutes of general meeting attached hereto as Annex 1.

As the company's liquid assets are held in several currencies (USD, EUR and DKK), the liquidation proceeds will be distributed among the shareholders in a manner that, to the greatest extent possible, accommodates each shareholder's highest-priority currency, followed by such shareholder's next-priority currency. The company will, however, not exchange any existing currency holdings, which means that some shareholders' preferences may only be met in part. In addition, withholding taxes will be settled in DKK. Conversion between the different currencies will be made using the exchange rates between DKK, EUR and USD published by the National Bank of Denmark (Danmarks Nationalbank) on the date of the general meeting. For a more detailed description, reference is made to Annex 1.

Item (d):

The liquidator proposes that the chairperson, with a right of substitution, be authorised to file the adopted resolutions with the Danish Business Authority and to make any such amendments and additions to the filing and the resolutions as may be required as a condition for registration, substantially in accordance with the draft minutes of general meeting attached hereto as Annex 1.

Majority requirements

The proposals under agenda items (b) and (d) may be adopted by a simple majority of votes. The proposal under agenda item (c) may be adopted by at least two-thirds of the votes cast and of the share capital represented at the general meeting.

Share capital

The share capital of the company is DKK 1,014,735.62 divided into 101,473,562 shares of DKK 0.01 each. Each share of DKK 0.01 carries one vote.

Record date

The record date is 19 November 2025 end of day (CET).

Participation and voting rights

The right of a shareholder to attend and vote at a general meeting is determined by the shares held by the shareholder at the record date.

The number of shares held by each shareholder at the record date shall be calculated based on (i) the number of shares registered in the company's register of shareholders and (ii) any notification of ownership received by the company but not yet registered in the company's register of shareholders.

For practical reasons, shareholders are encouraged to vote by correspondence or submit a proxy to the liquidator in accordance with the instructions below.

The extraordinary general meeting will be conducted in Danish. Participation is conditional on the shareholder having requested an admission card in due time.

How to obtain an admission card

Access to the extraordinary general meeting is conditional on the shareholder having requested an admission card by 21 November 2025 end of day (CET).

Admission cards for the extraordinary general meeting may be obtained by:

- returning the attached request for admission card form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

How to submit a proxy

Proxies must be received by the company by 21 November 2025 end of day (CET).

A proxy may be granted by:

- returning the attached proxy form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

The liquidator welcomes the submission of proxies from shareholders who are unable to attend the general meeting, authorising the liquidator to exercise the voting rights attached to their shares, in order to be informed of the shareholders' positions on the items on the agenda.

According to Danish company law, a proxy issued for the general meeting is only valid if it is in writing and dated.

How to vote by correspondence

Shareholders may vote by correspondence no later than 25 November 2025 end of day (CET) by which time the votes must have been received by the company:

- by returning the attached voting by correspondence form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Attn. Kristian Bojsen.

Votes by correspondence cannot be withdrawn.

Information on the website

Further information on the general meeting will be available on www.forward-pharma.com → 'Investors' until and including the date of the extraordinary general meeting, including:

- The notice convening the general meeting, including the draft minutes of general meeting attached hereto as Annex 1.
- Outline of the total number of shares and voting rights on the date of the notice.
- Documents to be presented at the general meeting: Final liquidation accounts.
- The agenda and the complete proposals.
- The forms to be used for voting by proxy or voting by correspondence.

11 November 2025

The liquidator of Forward Pharma A/S (In voluntary liquidation)